Back to top
more

Amgen (AMGN)

(Real Time Quote from BATS)

$285.22 USD

285.22
1,069,622

+0.55 (0.19%)

Updated Aug 7, 2025 01:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Zacks Equity Research

Teva (TEVA) to Report Q4 Earnings: What's in the Cards?

Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.

Sheraz Mian headshot

Top Stock Research Reports for Alphabet, Roche & Amgen

Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Roche Holding (RHHBY) and Amgen (AMGN).

Zacks Equity Research

Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates

Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.

Zacks Equity Research

Sanofi (SNY) Q4 Earnings Top, Sales Miss, Dupixent Strong

Sanofi (SNY) reports mixed fourth-quarter results with strong Specialty Care and Vaccines sales but soft Consumer Healthcare sales

Zacks Equity Research

Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal

Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan.

Zacks Equity Research

KB Home, National Beverage, Amazon, Visa and Amgen highlighted as Zacks Bull and Bear of the Day

KB Home, National Beverage, Amazon, Visa and Amgen highlighted as Zacks Bull and Bear of the Day

Zacks Equity Research

Amgen (AMGN) Stock Down Despite Q4 Earnings & Revenue Beat

Amgen (AMGN) stock declines despite better-than-expected fourth-quarter 2019 results. Its 2020 earnings guidance falls short of expectations.

Mark Vickery headshot

Amazon Beats Big on Q4 Bottom Line; Plus V, AMGN

Expectations for Q4 earnings were on the low side, both at Zacks and on the street, so take this giant bottom-line beat with a grain of salt.

Zacks Equity Research

Amgen (AMGN) Q4 Earnings and Revenues Surpass Estimates

Amgen (AMGN) delivered earnings and revenue surprises of 5.81% and 3.18%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Economic Data Deluge

Economic Data Deluge

Zacks Equity Research

Lilly (LLY) Q4 Earnings and Sales Top Estimates, Stock Up

Eli Lilly's (LLY) Q4 earnings and sales beat estimates. Shares rise in pre-market trading.

Mark Vickery headshot

Q4 GDP 2.1%, In-Line with Q3; Plus Q4 Earnings from VZ, KO & More

Q4 GDP hit the tape ahead of today's opening bell, with results better than analysts had been predicting: +2.1% was 30 basis points higher than the 1.8% expected.

Zacks Equity Research

Roche (RHHBY) 2019 Sales Solid on Robust Show by New Drugs

Roche's (RHHBY) performance in 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.

Zacks Equity Research

Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More

Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.

Zacks Equity Research

Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?

While Amgen's (AMGN) drugs like Prolia & Xgeva are expected to have done well, slowdown in sales of mature products are likely to have weighed on fourth-quarter sales.

Sweta Killa headshot

What Lies Ahead for Healthcare ETFs in Q4 Earnings?

With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.

Zacks Equity Research

Will Pfizer's (PFE) BioPharma Unit Boost Its Q4 Earnings?

Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, Ibrance in the Biopharma segment are likely to have made up for lower sales in the Upjohn group.

Zacks Equity Research

Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

Zacks Equity Research

Roche's (RHHBY) Lymphoma Drug Polivy Gets Approval in Europe

Roche (RHHBY) obtains approval for Polivy in Europe for the treatment of adult patients with R/R DLBCL.

Sheraz Mian headshot

Top Stock Reports for Alphabet, JPMorgan & Comcast

Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), JPMorgan Chase (JPM) and Comcast (CMCSA).

Zacks Equity Research

Should Value Investors Consider Amgen (AMGN) Stock Now?

Let's see if Amgen (AMGN) stock is a good choice for value-oriented investors right now from multiple angles.

Zacks Equity Research

Biogen Acquires Early-Stage CNS Drug From Pfizer for $75M

Biogen (BIIB) signs deals with Pfizer to acquire rights to a CNS candidate and develop it as potential therapy to treat certain symptoms/disorders related to Alzheimer's disease and Parkinson's disease.

Zacks Equity Research

Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - January 13, 2020

Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.